Why Chitosan? From properties to perspective of mucosal drug delivery

Kumar, Awanish; Vimal, Archana

doi:10.1016/j.ijbiomac.2016.05.054

Cited by 176 publications

(110 citation statements)

References 56 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…5 shows the percentage of unbounded mucin after incubation of mucin and the chitosan particles, and it can be observed that all the samples do not seem to show high mucoadhesive properties. It was expected that the higher DD of chitosan it should have a clear effect on a higher mucoadhesion of particles, due to more -NH 2 groups available to interact with the mucus (47). From the results in this study, no clear trends were observed.…”

Section: Mucoadhesionmentioning

confidence: 57%

Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles

et al. 2018

View full text Add to dashboard Cite

Chitosan particles loaded with the antigen ovalbumin (OVA) and the adjuvant, Quil-A were produced by electrospray, using mixtures of water/ethanol/acetic acid as a solvent. Three different chitosan's designed as HMC + 70, HMC + 85 and HMC + 90 (designated as 705010, 855010 and 905010) were tested and its efficacy to be used in oral vaccine delivery applications was investigated. The morphology, size and zeta potential of the produced particles were investigated, together with the encapsulation efficiency and release of OVA from the three chitosan formulations. Moreover, the mucoadhesion and cytotoxicity the chitosan microparticles was examined. All the three formulations with OVA and Quil-A were in the micrometer size range and had a positive zeta potential between 46 to 75 mV. Furthermore, all the three formulations displayed encapsulation efficiencies above 80 % and the release of OVA over a period of 80 h was observed to be between 38-47 %. None of the developed formulations exhibited high mucoadhesive properties, either cytotoxicity. The formulation prepared with HMC + 70, OVA and Quil-A had the highest stability within 2 h in buffer solution, as measured by dynamic light scattering. The electrosprayed formulation consisting of HMC + 70 with OVA and Quil-A showed to be the most promising as an oral vaccine system.

show abstract

Section: Mucoadhesionmentioning

confidence: 57%

Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The advantages by delivering drug through buccal route include; increased bioavailability, less amount of drug required and bypassing the hepatic first pass effect. Moreover, the drug need not be exposed to the harsh GI environment [81]. The high permeability of buccal mucosa is a suitable target for novel formulations [82].…”

Section: Mucoadhesionmentioning

confidence: 99%

“…Due to its properties of mucoadhesivity, permeation enhancement, biocompatibility, biodegradability and efflux pump inhibition, chitosan is one of the most suitable polymers for oral drug delivery [81]. In the above section on oral drug delivery with chitosan formulations, there are a few examples of mucoadhesive drug delivery systems there were formulated to release drug in the small intestine [40,41].…”

Section: Mucoadhesionmentioning

confidence: 99%

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

et al. 2017

View full text Add to dashboard Cite

The focus of this review is to provide an overview of the chitosan based nanoparticles for various non-parenteral applications and also to put a spotlight on current research including sustained release and mucoadhesive chitosan dosage forms. Chitosan is a biodegradable, biocompatible polymer regarded as safe for human dietary use and approved for wound dressing applications. Chitosan has been used as a carrier in polymeric nanoparticles for drug delivery through various routes of administration. Chitosan has chemical functional groups that can be modified to achieve specific goals, making it a polymer with a tremendous range of potential applications. Nanoparticles (NP) prepared with chitosan and chitosan derivatives typically possess a positive surface charge and mucoadhesive properties such that can adhere to mucus membranes and release the drug payload in a sustained release manner. Chitosan-based NP have various applications in non-parenteral drug delivery for the treatment of cancer, gastrointestinal diseases, pulmonary diseases, drug delivery to the brain and ocular infections which will be exemplified in this review. Chitosan shows low toxicity both in vitro and some in vivo models. This review explores recent research on chitosan based NP for non-parenteral drug delivery, chitosan properties, modification, toxicity, pharmacokinetics and preclinical studies.

show abstract

“…As chitosan is one of the most exploited polymers in biomedical science [10], and in broadly recognized by its mucohadesive properties [12,13] this polymer could be considered as an opportunity to construct platforms of intranasal vaccines against pneumococcal pneumoniae and meningococcal meningitis, as they are severe infections that affects children in several countries. Results from PsaA studies [14] and PSC-MenC vaccines [8] on state of art, are important to reinforce mucosal vaccines for bacterial infections from respiratory tract as an alternative of immunization, exploiting the natural way of contamination of these diseases.…”

Section: Resultsmentioning

confidence: 99%

“…Its molecular weight and chemical modifications are responsible for physical-chemical proprieties as solubility. In acid solutions, chitosan is soluble and charged positively and neutral and alkaline, it is insoluble [9,10]. Due its safety and biocompatibility for topical and oral use, chitosan was been used in several pharmaceutical applications, as constituent of matrix for encapsulation and immobilization of drugs and also as a mucoadhesive material and as a transmucosal absorption promoter [11].…”

Section: Chitosan Polymer In Studies For Pharmaceutical Applicationsmentioning

confidence: 99%

Evaluation of Mucosal Vaccines against Pneumococcal and Meningococcal Diseases

Santos

Pereira

Miguez

et al. 2017

IJVV

View full text Add to dashboard Cite

show abstract

Why Chitosan? From properties to perspective of mucosal drug delivery

Cited by 176 publications

References 56 publications

Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles

Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

Evaluation of Mucosal Vaccines against Pneumococcal and Meningococcal Diseases

Contact Info

Product

Resources

About